Literature DB >> 21876080

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

Marina Chiara Garassino, Silvia Marsoni, Irene Floriani.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21876080     DOI: 10.1200/JCO.2011.36.7847

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.

Authors:  Sema Bircan; Huseyin Baloglu; Zafer Kucukodaci; Ahmet Bircan
Journal:  Med Oncol       Date:  2014-06-29       Impact factor: 3.064

2.  LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

Authors:  Y M Whang; S I Park; I A Trenary; R A Egnatchik; J P Fessel; J M Kaufman; D P Carbone; J D Young
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

3.  Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.

Authors:  Gerald S M A Kerner; Ed Schuuring; Johanna Sietsma; Thijo J N Hiltermann; Remge M Pieterman; Gerard P J de Leede; John W G van Putten; Jeroen Liesker; Tineke E J Renkema; Peter van Hengel; Inge Platteel; Wim Timens; Harry J M Groen
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

4.  Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.

Authors:  Wenjing Yang; Yibo Gao; Xuelian Li; Jing Zhang; Tiejun Liu; Xiaoli Feng; Hao Pan; Xiaofan Yang; Shuanghua Xie; Xiaoshuang Feng; Zhangyan Lv; Yonggang Wang; Zhaoli Chen; Jie He
Journal:  World J Surg Oncol       Date:  2017-11-06       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.